Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Treasury Shares (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Treasury Shares for 9 consecutive years, with $450916.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 39.94% year-over-year to $450916.0, compared with a TTM value of $450916.0 through Dec 2025, down 39.94%, and an annual FY2025 reading of $450916.0, down 39.94% over the prior year.
  • Treasury Shares was $450916.0 for Q4 2025 at VYNE Therapeutics, down from $750715.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $750715.0 in Q4 2024 and bottomed at $70133.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $363271.8, with a median of $450916.0 recorded in 2025.
  • The sharpest move saw Treasury Shares plummeted 90.25% in 2021, then skyrocketed 451.3% in 2023.
  • Year by year, Treasury Shares stood at $70133.0 in 2021, then grew by 19.22% to $83616.0 in 2022, then surged by 451.3% to $460979.0 in 2023, then soared by 62.85% to $750715.0 in 2024, then crashed by 39.94% to $450916.0 in 2025.
  • Business Quant data shows Treasury Shares for VYNE at $450916.0 in Q4 2025, $750715.0 in Q4 2024, and $460979.0 in Q4 2023.